Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature

Elodie Boissier; Steve Genebrier; Karim Lakhal; Fabienne Nedelec-Gac; Marc Trossaërt; Catherine Ternisien; Isabelle Gouin-Thibault

doi:10.1055/s-0038-1661391

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(08): 1488-1490
DOI: 10.1055/s-0038-1661391

Letter to the Editor

Georg Thieme Verlag KG Stuttgart · New York

Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature

Elodie Boissier

¹Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France

,

Steve Genebrier

²Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France

,

Karim Lakhal

³Anesthésie-Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France

,

Fabienne Nedelec-Gac

²Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France

,

Marc Trossaërt

¹Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France

⁴Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France

,

Catherine Ternisien

¹Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France

⁴Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France

,

Isabelle Gouin-Thibault

²Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France

› Author Affiliations

Abstract

Full Text

References

References
1 Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760
2 Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016; 14 (05) 886-893
3 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
4 Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (06) 1308-1313
5 McGrail R, Revsholm J, Nissen PH, Grove EL, Hvas AM. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res 2016; 148: 107-110
6 Schmitz EMH, Boonen K, van den Heuvel DJA. , et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014; 12 (10) 1636-1646
7 Albaladejo P, Bonhomme F, Blais N. , et al; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med 2017; 36 (01) 73-76
8 Gouin-Thibault I, Freyburger G, de Maistre E. , et al; GFHT study group on DOAC. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. Thromb Res 2017; 158: 126-133